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Clinical background
C-type natriuretic peptide (CNP) is a 22-amino-acid pep-
tide produced mainly in the endothelium and is a ligand
for a guanylyl cyclase-coupled receptor, the NPR-B recep-
tor. Recent studies have revealed that in overt heart failure
(HF), the predominant natriuretic peptide (NP) receptor
in the kidney is the NPR-B receptor. CNP has a potent car-
diac unloading action and reduces blood pressure but has
minimal renal actions. Based on our previous knowledge,
we altered the amino acid (aa) sequence in the ring struc-
ture of CNP and fused a 5 aa sequence from ANP to the N-
terminus and a 6 aa sequence from BNP to the C-terminus
of CNP. We hypothesized that this novel hybrid peptide
ABC-NP would maintain CNP's inherent cardiac unload-
ing characteristics plus gaining renal enhancing properties
without hypotensive effects.
Methods
We determined the cardiorenal and humoral actions of
intravenous infusion of ABC-NP at 2 pmol/kg/min, 10
pmol/kg/min and 100 pmol/kg/min in 7 dogs with rapid
ventricular pacing induced overt HF with cardiorenal dys-
function (240 bpm for 10 days). * p < 0.05.
Results
IV infusion of ABC-NP enhanced glomerular filtration
rate (GFR), from 31 ± 5 to 45 ± 7, 51 ± 6 and 60 ± 7 ml/
min*, induce natriuresis (from 3 ± 2 to 12 ± 8, 17 ± 13 and
29 ± 19 μEq/min*) and diuresis (from 0.13 ± 0.03 to 0.4
± 0.1, 0.6 ± 0.2 and 0.8 ± 0.3 ml/min*) with a modest
reduction in pulmonary capillary wedge pressure (PCWP)
(from 21 ± 1 to 19 ± 1, 20 ± 1 and 21 ± 1 mmHg*). Impor-
tantly, mean arterial blood pressure was maintained.
These actions were associated with suppression of plasma
renin and increases in urinary cGMP* excretion.
Conclusion
We report for the first time that this novel peptide ABC-NP
has potent natriuretic and GFR enhancing actions without
hypotensive properties in an experimental model of overt
CHF. This renal specific peptide may have potential ther-
apeutic benefit in states of renal dysfunction with volume
overload to enhance GFR and sodium excretion without
the detrimental side effect of hypotension.
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